风 潮 如 螺 旋 般 上 升 ， 不 断 循 环 同 时 也 不 断 进 步 。 这 似 乎 是 美 妆 行 业 永 恒 的 规 律 。 早 在 1 9 8 0 年，Sisl e y推出的经典全能乳液，凭借"一瓶全效，终极保养"的功效承诺风靡全球；1 8年前， OLAY 多 效 修 护 面 霜 成 为 当 年 的 大 爆 品 。 后 来 伴 随 成 分 党 崛 起 ， 品 牌 们 用 消 费 者 对 玻 色 因 、 3 7 7等高效成分的崇拜统领市场，靶向精准、专一强效成为了研发"圣经"。 到今天，风向似乎又回潮到"多而全"：精华开始抗氧/美白/修护三效a ll i n，防晒霜不仅防晒 还得防黑防老，彩妆更是要化身"全能战士"，恨不能一盒解决全脸妆容。 从全能风靡到专效 神坛、再回归如今的多效狂欢，美妆赛道似乎又画出了一个轮回。这究竟是消费理性的终极进 化，还是新一轮营销内卷的开端？能否推动市场走向更理性、更精简的未来？ 放眼当下的美妆市场，一股"一瓶多效"的风潮正以前所未有的力度席卷核心品类。 《FBe a u t y 未来迹》发现，2 0 2 5年以来，品牌们在升级经典单品或推出新品时，都不约而同地将" ...

近日，国家药监局在广州召开化妆品备案管理智能化转型工作视频会，会上强调围绕高水平安全、高质量发展、高效能治理的化妆品智能化转型方向，但同 时也提出要全面加强化妆品智慧监管能力建设，不断提升化妆品监管信息化、数字化和智能化水平。 化妆品生产与运营的智能化已经是行业大势所趋，以七大头部企业为例： 作者：苏苏 来源：首席消费官 以"药+妆"祛痘为核心理念的贝泰妮，构建了"AI诊断+个性化方案+私域服务"全链路； 华熙生物的AI战略则是通过"技术+生态+产业链"的三维布局，推动企业从生物制造向生物智造升级； 珀莱雅的布局则是以"技术+组织+全球化"为战略方向，企图构建科技驱动的美妆生态； 上海家化通过研发、定制化、数据资产三位一体，力争将技术优势转化为产品价值。 整体来看，国内头部美妆企业呈现拥抱AI的态度积极、AI应用场景多元、AI的应用到基础运营向高端开发跃迁、对于AI的投入从单一场景试水向生态布局 升级的现状。而此次监管的提示，也预示着美妆产业智能化将从野蛮生长向规范化路径转变。 从运营到研发 AI的深度技术融合 据年报披露，福瑞达2024年致力于推进理想皮肤微生态研究与AI数据模型开发，实施研发投入刚性增长机 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating potential growth opportunities in the sector [2]. Core Insights - The domestic brands showcased strong performance on Douyin, with Feicui achieving a GMV of nearly 500 million, marking a new high for the year [6][12]. - The cosmetics and medical beauty sector performed in line with the market, with the Shenwan Beauty Care Index rising by 1.6% from May 30 to June 6, 2025 [6][7]. - International cosmetic companies are experiencing a decline or slowdown in growth, with L'Oréal's Q1 2025 revenue growth at 4.4%, and Estée Lauder facing a significant drop in revenue and operating profit [13][15][16]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index increased by 1.6%, while the Shenwan Cosmetics Index rose by 0.7%, slightly underperforming the Shenwan A Index [6][7]. - Domestic brands like Marubi and Yilian have shown over 50% growth in skincare, while color cosmetics brands like Caitang and Maogeping achieved over 70% growth [12]. Key Developments - Leping Medical's "童颜针" (Youthful Needle) received approval, marking a competitive entry into the domestic market for facial fillers [26]. - Furuida's synthetic royal jelly acid (10-HDA) has achieved industrialization, providing a high-purity ingredient for anti-aging products [27]. Investment Recommendations - Recommended stocks include: 1. Upstream companies with strong R&D capabilities and profitability, such as Aimeike [17]. 2. Brands benefiting from Douyin traffic, like Marubi [17]. 3. Companies with strong product innovation and cost-effectiveness, such as Runben and Furuida [17]. - Suggested to pay attention to Shanghai Jahwa, Betaini, Huaxi Biological, and Water Sheep [17]. Market Trends - The cosmetics market in China is projected to grow, with a retail sales increase of 7.2% in April 2025, indicating a recovery in consumer demand [23][25]. - The market share of domestic brands in the skincare segment has improved significantly, with domestic brands occupying five out of the top ten positions in market share [36][37].

Core Viewpoint - The ongoing controversy surrounding the collagen content claims by Juzhi Biotechnology highlights a deeper crisis of trust within the skincare industry, exacerbated by a lack of transparency and regulatory standards [1][2][3]. Group 1: Industry Trust Issues - The dispute over ingredient authenticity has revealed significant gaps in consumer trust and industry standards, with companies often engaging in "black box" practices that obscure the true efficacy of their products [3][4]. - The skincare sector is facing a crisis where consumers are increasingly skeptical of scientific claims, demanding transparency and accountability from brands [3][10]. Group 2: Regulatory and Market Dynamics - Recent events, including a fine imposed on CSS for false advertising, illustrate the consequences of misleading marketing practices, with penalties disproportionately affecting downstream partners rather than brands [6][9]. - The market for soluble collagen and other active ingredients is experiencing explosive growth, with a reported 106.93% increase in soluble collagen registrations, indicating a shift in consumer preferences towards these components [6][9]. Group 3: Ingredient Efficacy and Marketing Practices - The industry is grappling with two main issues: the imbalance in quantifying ingredient efficacy and the use of "shadow ingredients" to mislead consumers about product value [7][8]. - Companies are often reducing the actual amounts of active ingredients to cut costs, leading to a significant disparity between product claims and actual performance, which undermines consumer trust [7][8]. Group 4: Future Opportunities and Challenges - The lack of standardized testing methods and regulatory frameworks is creating a fragmented market where companies can exploit loopholes, leading to a potential collapse of consumer confidence [10][11]. - The need for an open and transparent verification platform is critical for establishing trust and setting future industry standards, as current practices are failing to meet consumer expectations [10][11].

Core Viewpoint - The controversy surrounding ergothioneine, a compound linked to anti-aging, has intensified following accusations of it being a "fake drug" due to lack of sufficient evidence for its approval as a medicine. Companies like Kelun Pharmaceutical and its subsidiary have defended ergothioneine's classification as a health management tool rather than a drug, citing international studies that support its potential benefits [1][2][4]. Industry Overview - The global market for ergothioneine is projected to exceed $810.4 million by 2027, with a compound annual growth rate (CAGR) of 36.17% from 2021 to 2027. The raw material market for ergothioneine is also expected to grow from $6.3 million in 2024 to $16.1 million by 2031 [1]. - Companies such as Huaxi Biological and Chuaning Biological are accelerating their production capabilities through synthetic biology to meet the rising demand for high-purity ergothioneine [2][8]. Product Positioning and Pricing - Ergothioneine is marketed as a dietary supplement rather than a drug, with Kelun's product priced at 1499 yuan for 60 capsules, while competitors like Jinsan Biological offer similar products at 539 yuan. Kelun justifies its pricing based on Japanese market standards and production costs [4][5]. - The compound is recognized as a fifth-generation antioxidant and is used in both topical and oral applications, often combined with other ingredients like hyaluronic acid and collagen peptides [3][6]. Scientific Research and Development - Despite claims of ergothioneine's anti-aging effects, there are gaps in scientific understanding regarding its mechanisms and clinical validation. Research indicates that while ergothioneine shows promise, further studies are needed to explore its effects and applications in medicine [2][8]. - Companies are investing in research to better understand ergothioneine's potential, with Huaxi Biological planning to invest 1.35 million yuan in related projects [7]. Production and Supply Chain - The production of ergothioneine has historically faced challenges due to low yields from natural sources, but advancements in synthetic biology are enabling domestic companies to increase production capacity. For instance, Chuaning Biological plans to establish a facility capable of producing 0.5 tons of ergothioneine annually [6][8]. - The majority of ergothioneine is produced through microbial fermentation or enzyme catalysis, with domestic firms achieving over 99% purity in their products [8].

证券代码：600223 证券简称：福瑞达 编号：临 2025-017 鲁商福瑞达医药股份有限公司 关于高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于2025年6月4日召开了 第十二届董事会2025年第二次临时会议，审议通过了《关于公司高级管理人员变 动的议案》，现将相关内容公告如下： 一、高级管理人员离任情况 （二）离任对公司的影响 张红阳先生的离任不会影响公司日常经营活动。截至本公告披露日，张红阳 先生未持有公司股份，不存在应当履行而未履行的承诺事项，并已按照公司相关 规定做好交接工作。在公司董事会秘书空缺期间，由公司副总经理窦茜茜女士代 行董事会秘书职责（简历附后），公司将根据《公司法》《公司章程》及相关法 律、法规的规定，尽快完成董事会秘书的聘任工作。 公司董事会对张红阳先生任职期间为公司发展所做的贡献表示衷心的感谢！ 二、聘任高级管理人员的情况 公司第十二届董事会2025年第二次临时会议审议通过了《关于公司高级管理 人员变动的议案》，由副总经 ...

证券代码：600223 证券简称：福瑞达 公告编号：2025-018 鲁商福瑞达医药股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （一）股东大会类型和届次 （四）现场会议召开的日期、时间和地点 2024年年度股东大会 召开的日期时间：2025 年 6 月 25 日 14 点 30 分 （二）股东大会召集人：董事会 召开地点：山东省济南市高新区新泺大街 888 号公司会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 6 月 25 日 至2025 年 6 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当 ...

鲁商福瑞达医药股份有限公司 2024 年年度股东大会会议资料 目 录 议案一 2024 年度董事会工作报告 各位股东及股东代表： 2024 年，公司董事会严格遵守《公司法》《证券法》等法律法规， 切实履行股东大会赋予的董事会职责，勤勉尽职地开展各项工作，促 进公司持续、健康、稳定的发展。现将《2024 年度董事会工作报告》 提交本次股东大会，请各位股东及股东代表予以审议。 一、董事会会议情况及决议内容 2024 年度，公司董事会共召开会议 9 次，具体情况如下： （一）2024 年 2 月 5 日，公司第十一届董事会 2024 年第一次临 时会议以通讯方式召开，会议全票通过《关于授权副总经理代行总经 理职责的议案》。 （二）2024 年 2 月 27 日，公司第十一届董事会 2024 年第二次临 时会议以通讯方式召开，会议通过《关于控股子公司鲁商生活服务股 份有限公司转让山东省汇邦达装饰工程有限公司 100%股权暨关联交 易的议案》。 2025 年 6 月 25 日 | 议案一 | 2024 年度董事会工作报告 | 3 | | --- | --- | --- | | 议案二 | 2024 年度监事会工作报告 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-016 鲁商福瑞达医药股份有限公司 第十二届董事会 2025 年第二次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司第十二届董事会2025年第二次临时会议于 2025年5月30日发出通知，并于2025年6月4日以通讯方式召开。本次董事会由董 事长贾庆文先生召集，应参会董事5名，实际参加表决的董事5名，同时监事会成 员审阅了本次会议的议案，符合《公司法》和公司章程规定。 经参会董事审议表决，全票通过以下议案并形成如下决议： 一、通过《关于公司高级管理人员变动的议案》，因工作变动，张红阳先生 不再担任鲁商福瑞达医药股份有限公司副总经理、董事会秘书职务，由副总经理 窦茜茜女士代行董事会秘书职责。由副总经理（代行总经理职责）高春明先生提 名，经董事会提名委员会审核通过，聘任徐传彬先生为公司副总经理，任期与公 司第十二届董事会一致。具体内容详见《鲁商福瑞达医药股份有限公司关于高级 管理人员变动的公告》（临2025-017）。 ...

Group 1 - The core viewpoint of the article highlights a significant rise in beauty and personal care stocks, with Nobon Co., Ltd. hitting the daily limit up, indicating strong market interest and investor confidence in this sector [1] - Other companies in the beauty care sector, such as Jieya Co., Ltd., Shuiyang Co., Ltd., and Huaye Fragrance, also experienced notable gains, with increases exceeding 10% [1] - The National Bureau of Statistics reported that the total retail sales of consumer goods in April grew by 5.7% year-on-year, accelerating by 0.5 percentage points compared to March, indicating a positive trend in consumer spending [1] Group 2 - The retail sales of cosmetics specifically increased by 9.8%, significantly outpacing the overall growth rate of consumer goods, suggesting a robust demand for beauty products [1]